Blog
Latest articles, insights, and updates from the blog.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston-area clinics are spotlighting ketamine for depression and anxiety. Here's what their approach means for patients using at-home ketamine troches.
TMS vs. Ketamine: What TRD Patients Should Know
Medical Daily covers when to try ketamine or TMS for treatment-resistant depression. Here's what it means for patients weighing ketamine troches.
IV Ketamine in the News: What Troche Users Should Know
A FOX 4 Kansas City segment spotlights IV ketamine therapy. Here's what the growing media attention means for ketamine troche patients and at-home access.
Ketamine & Workers' Comp: What Alabama's Rules Mean
Alabama workers' comp cases are testing ketamine therapy coverage standards. Here's what this legal shift means for troche access and reimbursement in 2026.
Esketamine Clinic Protocols: What Troche Patients Should Know
New guidance on esketamine clinical setup highlights why ketamine troches remain a flexible, accessible alternative for many treatment-resistant depression patients.
NMDA Side Effects: What the Data Means for Troche Users
New research on NMDA antagonist side effects and discontinuation rates offers practical guidance for ketamine troche patients managing treatment-resistant depression.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Trump EO Could Reshape Ketamine Troche Access in 2026
President Trump's 2026 executive order on psychedelic research signals a regulatory shift that could affect compounded ketamine troche access and prescribing.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.
FDA Review of Preservative-Free Ketamine Advances
NRx Pharmaceuticals reports progress on FDA review of its preservative-free ketamine application. Here's what it could mean for troche access and compounding.
Ketamine Side Effects: What New Data Means for Troches
New research on NMDA antagonist side effects in treatment-resistant depression highlights why ketamine troches offer a distinct safety and tolerability profile.
NRx's FDA Push for Preservative-Free Ketamine Explained
NRx Pharmaceuticals reports FDA progress on a preservative-free ketamine application. Here's what it means for troche access, compounding, and home dosing.